Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | HTR1D | P28221 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16428909 | 1.00 | CA2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15211143 | 1.00 | CA2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1567100 | 0.87 | CA2 (0.54) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15219505 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15219843 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL406490 | 0.86 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15210953 | 0.84 | HTT (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL15210950 | 0.84 | HTT (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL11217487 | 0.84 | HTR1A (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL24113076 | 0.83 | HTT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241298-A1 | Liquid Sulfonylurea-Containing Herbicidal Compositions | BATTELLE UK LIMITED (GB) | 2025-07-31 | — | — | US | disclosed |
| US-12364261-B2 | Liquid sulfonylurea- and Li-salt containing herbicidal compositions | BATTELLE UK LIMITED (GB) | 2025-07-22 | — | — | US | disclosed |
| US-12268209-B2 | Liquid sulfonylurea-containing herbicidal compositions | MITSUI AGRISCIENCE INTERNATIONAL S.A./N.V. (BE) | 2025-04-08 | — | — | US | disclosed |
| CN-116250539-B | Ternary weeding composition containing fenpyrazamine and application thereof | 青岛清原化合物有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-117941690-A | Weeding composition containing tetrafluoro-clomazone and application thereof | 江苏清原农冠杂草防治有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117941696-A | Herbicidal compositions comprising fused ring substituted aromatic compounds and uses thereof | 江苏清原农冠杂草防治有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117941694-A | Herbicidal compositions comprising substituted pyrimidine formyl oximes and use thereof | 江苏清原农冠杂草防治有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024073018-A1 | BIODEGRADABLE MICROPARTICLES FOR REDUCING THE VOLATILITY OF BIXOLOZONE | FMC CORPORATION (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4138556-B1 | LIQUID SULFONYLUREA HERBICIDE COMPOSITION | BATTELLE UK LTD (GB) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023202364-A1 | HERBICIDAL COMPOSITION COMPRISING PYRIMIDINE FORMYL OXIME DERIVATIVE AND USE THEREOF | 青岛清原作物科学有限公司 | 2023-10-26 | — | — | WO | disclosed |
| WO-2001092249-A2 | CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES | COR THERAPEUTICS, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001087871-A2 | METHODS FOR PRODUCING AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| US-5925662-A | OXIDASE INHIBITORS | SYNTHELABO (FR) | 1999-07-20 | — | — | US | disclosed |
| EP-0859776-A1 | COMPOUNDS DERIVED FROM OXAZOLIDIN-2-ONE AND PREPARATION AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997017347-A1 | COMPOUNDS DERIVED FROM OXAZOLIDIN-2-ONE AND PREPARATION AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
| US-4208333-A | Preparation of chroman-2-acetic acids | HOFFMANN-LA ROCHE INC. (US) | 1980-06-17 | — | — | US | disclosed |
| US-4208333-A | Preparation of chroman-2-acetic acids | HOFFMANN-LA ROCHE INC. (US) | 1980-06-17 | — | — | US | disclosed |
| US-4192816-A | Mixtures of 3-pentenenitriles and 3-methylene-pentanenitriles | HOFFMANN-LA ROCHE INC. (US) | 1980-03-11 | — | — | US | disclosed |
| US-4186138-A | Preparation of chroman-2-acetic acids | HOFFMANN-LA ROCHE INC. (US) | 1980-01-29 | — | — | US | disclosed |
| US-4186138-A | Preparation of chroman-2-acetic acids | HOFFMANN-LA ROCHE INC. (US) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364261-B2 | Liquid sulfonylurea- and Li-salt containing herbicidal compositions | LCT, CLIC1, CLIC4 | CA2 19/4885HTR1A 3473/4885SIGMAR1 316/4885 |
| US-12268209-B2 | Liquid sulfonylurea-containing herbicidal compositions | CA2, CA3, DPP4 | CA2 1/4885HTR1A 4289/4885SIGMAR1 501/4885 |
| US-20250241298-A1 | Liquid Sulfonylurea-Containing Herbicidal Compositions | CA2, CA3, DPP4 | CA2 1/4885HTR1A 4289/4885SIGMAR1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.